Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
SOUTH ORANGE, NJ - Nephros, Inc. (NASDAQ:NEPH), a $21.31M market cap company known for its water filtration solutions with impressive gross profit margins of 61.59%, today announced the introduction of the S100 In-Line filter, broadening its infection control portfolio. According to InvestingPro data, the company maintains strong financial health with a current ratio of 5.31. The latest addition to the S100 microfiltration series offers enhanced installation flexibility, catering to both clinical and non-clinical settings.
The S100 In-Line filter is designed to facilitate bacterial retention and can be installed in various environments, including emergency eyewash stations, pharmaceutical labs, dental equipment, and recreational vehicle water systems. This model complements existing sink and shower filters, providing a solution for low-pressure plumbing scenarios where traditional filters are unsuitable. The company’s innovation comes as its stock has shown strong momentum, with a 44.08% return over the past six months.
Maintaining the S100 line’s safety and performance standards, the new filter has a 0.1-micron pore size and is FDA 510(k)-cleared as a Class II medical device. It also boasts an increased flow rate, a lifespan of up to 90 days, and meets ASTM F838 standards for bacterial retention.
Robert Banks, President & CEO of Nephros, emphasized the practicality of the S100 In-Line microfilter in addressing specific installation needs and expanding the company’s water safety solutions. The product is available in Quick Connect and Threaded configurations, with two installation kits for ease of integration across diverse settings.
This launch signifies Nephros’s commitment to bridging the gap between microfiltration and ultrafiltration technologies, aiming to provide a comprehensive and versatile portfolio for water safety.
Information based on a press release statement indicates that the S100 In-Line microfilter is now available for purchase, targeting a wider range of applications and environments.
In other recent news, Nephros Inc. reported a strong financial performance for the fourth quarter of 2024, surpassing earnings expectations. The company achieved an earnings per share (EPS) of $0.03, which exceeded the forecasted -$0.02, marking a notable turnaround from previous losses. Nephros also recorded a 19% year-over-year increase in revenue, reaching $3.9 million for the quarter. This growth was attributed to the company’s strategic focus on expanding its market presence and introducing new products. Furthermore, Nephros achieved positive net income of $349,000, compared to a loss of $654,000 in the same period last year. The company continues to explore new verticals beyond healthcare, such as airports and schools, to bolster its growth. Analysts have noted Nephros’s resilience and strategic initiatives as key factors in its improved financial standing. Additionally, the launch of the 20-inch HydroGuard Ultra Filter aligns with regulatory standards, enhancing the company’s competitive position in the sterile processing market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.